Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat
Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.
Escalating State-Level Scrutiny on PBM Vertical Integration
The recent lawsuit filed by Express Scripts, a Cigna subsidiary, and the Pharmaceutical Care Management Association (PCMA) against Tennessee's FAIR Rx Act marks a critical escalation in state-level regulatory pressure on Pharmacy Benefit Managers (PBMs). This action, initiated on June 14, 2026, mirrors a prior challenge by CVS Caremark in May, targeting a law passed earlier this year despite significant PBM opposition. The FAIR Rx Act, slated for implementation in 2028, directly prohibits PBMs from owning pharmacies and restricts their mail-order services within Tennessee. This legislative trend is not isolated; Arkansas enacted a similar bill last year, which was subsequently enjoined following challenges from Express Scripts, CVS Caremark, and UnitedHealth’s OptumRx. Furthermore, at least nine other states are actively considering comparable legislation to restrict PBM ownership of pharmacies. For procurement directors and supply chain VPs, this signals a systemic shift in the regulatory landscape, demanding a proactive assessment of PBM relationships and potential operational disruptions across multiple states. The collective influence of these PBMs, which control approximately 80% of all U.S. prescriptions, means that any successful state-level restrictions could trigger widespread changes in drug distribution and access, necessitating immediate strategic re-evaluation.
Drivers: Unpacking Anti-Competitive Concerns Fueling PBM Legislation
The impetus behind Tennessee's FAIR Rx Act and similar state initiatives stems from widespread concerns regarding the market power of vertically integrated PBMs. Independent pharmacies have long contended that major PBMs leverage their dual role as benefit managers and pharmacy owners to create an anti-competitive environment. Specific allegations include restricting reimbursement rates, forcing independent pharmacies into unfavorable contracts, actively steering patients towards PBM-owned in-house pharmacies, and clawing back revenue through various fees. These concerns are not unfounded; federal regulators have identified instances where PBMs provide preferential payment rates to their own pharmacies, a practice that contributes to the closure of independent pharmacies and consequently limits patient access to prescription drugs. This legislative push by states is largely a response to a perceived gap left by Congress, which, despite bipartisan interest, has yet to pass comprehensive PBM reform addressing the core issue of joint PBM-pharmacy ownership. For regulatory affairs heads, understanding these underlying anti-competitive drivers is crucial for anticipating future legislative efforts. It necessitates developing compliance strategies that not only adhere to current regulations but also proactively address perceived conflicts of interest and market power imbalances to mitigate future regulatory risks.
Who Is Most Exposed: Major PBMs Face Significant Operational and Financial Disruption
The FAIR Rx Act poses substantial operational and financial threats to major PBMs and their affiliated entities. CVS Caremark, for instance, has stated that the law would compel the closure of 136 retail and specialty pharmacies in Tennessee and force a halt to its mail-order services within the state. Similarly, Express Scripts, a Cigna subsidiary, faces significant disruption. The company asserts that the law would force it to cease shipping medications to Tennessee residents, affecting access for tens of thousands, particularly those requiring specialized or hard-to-find drugs. More critically, Express Scripts would be forced to close its dispensing facility in Memphis. This facility is a cornerstone of the company's national operations, managing approximately $900 million in inventory on any given day and distributing drugs to nearly half a million patients across the country. The potential closure of such a critical hub highlights the far-reaching supply chain implications beyond Tennessee's borders. For supply chain VPs and business development executives, this exposure necessitates an immediate and thorough assessment of their reliance on these PBMs for distribution, especially for high-value or specialty pharmaceuticals. Modeling potential disruptions to patient access, inventory management, and overall distribution networks is paramount to safeguarding commercial interests and ensuring continuity of care.
Legal Battlegrounds: Constitutional Challenges and Precedent from Arkansas
The lawsuits filed by Express Scripts and the PCMA against Tennessee's pharmacy board and attorney general leverage arguments nearly identical to those presented by CVS Caremark. The core of their legal challenge asserts that the FAIR Rx Act is unconstitutional, specifically violating the Dormant Commerce Clause by discriminating against out-of-state businesses. Furthermore, the PBMs contend that the state law is preempted by multiple federal statutes, including the Employee Retirement Income Security Act (ERISA), which governs nationwide employee benefits plans, and TRICARE, which provides benefits for military members and their families. Andrea Nelson, Cigna’s general counsel, articulated the company's position, stating, “We’re deeply troubled by this law’s blatant prioritization of special interests and political agendas over the health of patients and a competitive marketplace.” PCMA CEO and President David Marin echoed this sentiment, expressing confidence in the court's recognition of the law's harmful and unconstitutional nature. This legal strategy has a precedent; Arkansas signed a similar bill into law last year, but it was enjoined last summer following successful challenges from Express Scripts, Caremark, and UnitedHealth’s OptumRx. For regulatory affairs teams, closely monitoring the progression of these legal battles is critical. Court decisions will establish vital precedents that could either embolden other states to pursue similar PBM restrictions or reinforce the PBMs' existing operating models, directly influencing the future regulatory landscape for the chemical and life sciences industry.
Strategic Imperatives for the Chemical and Life Sciences Industry
Given the escalating regulatory challenges to PBM business models, senior decision-makers in the global chemical and life sciences industry must adopt proactive strategies. First, procurement directors should immediately evaluate their current reliance on PBM-owned pharmacies and mail-order services, particularly for high-volume or specialty medications. Identifying and vetting alternative distribution channels and partners is crucial to mitigate potential supply chain disruptions. Second, regulatory affairs heads must establish robust, real-time monitoring systems for PBM-related legislative and judicial developments across all 50 states, not just those currently considering new laws. This includes tracking the outcomes of the Tennessee and Arkansas lawsuits, as these will set critical precedents. Third, business development executives should engage proactively with industry associations and policymakers. Advocating for balanced legislation that addresses anti-competitive concerns while preserving patient access and market stability is essential. Finally, supply chain VPs must conduct comprehensive risk assessments that model the impact of potential PBM divestitures or service restrictions on drug access, inventory management, and patient adherence. Developing contingency plans for maintaining drug flow to affected regions, especially for specialized, hard-to-find drugs, will be paramount to safeguarding commercial interests and ensuring uninterrupted patient care in a rapidly evolving regulatory environment.